Thursday, August 27, 2015

PharmGKB Pathway Peginterferon-α published in Pharmacogenetics and Genomics



The PharmGKB summary:  peginterferon-α pathway has been published in the Pharmacogenetics and Genomics Journal. Peginterferon-α (pegylated interferon-α or PEG-IFN-α) is an antiviral drug used to treat chronic hepatitis C virus (HCV) infection. The PharmGKB review summarizes the pharmacokinetics and pharmacodynamics of peginterferon-α and also discusses genetic variations around the IFNL3 locus (formerly known as IL28B) affecting the viral clearance and clinical responses to peginterferon-α based therapy.
  
Find out more...
View interactive Peginterferon-α pathway on PharmGKB.

Read our new publication:
Pharmacogenet Genomics. 2015 Sep; 25(9):465-74
Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. 
PMID: 26111151

View all pathways on PharmGKB.

Tuesday, August 4, 2015

The National Institutes of Health Awards $14 million to Stanford Researchers for Precision Medicine Projects

The National Institute for General Medical Sciences (NIGMS) has awarded a $10 million grant to Dr. Teri Klein and Dr. Russ Altman to continue and expand the Pharmacogenomics Knowledgebase (PharmGKB), the premier resource for curated knowledge about the impact of human genetic variation on drug responses. In addition, Dr. Klein and Dr. Mary Relling, PharmD, Chair of Pharmaceutical Sciences at St. Jude Children’s Hospital were also awarded a $4 million grant from the NIGMS and National Human Genome Research Institute (NHGRI) to fund the Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC publishes guidelines that enable the translation of genetic tests into actionable prescribing decisions for specific drugs.

Read the press release from the Stanford Medicine News Center below: